Form 4: Calidi Biotherapeutics Director Alan R. Stewart Reports Stock Transactions

Alan R. Stewart, a director at Calidi Biotherapeutics, reported the acquisition and disposal of common stock on December 31, 2024, according to a Form 4 filing with the SEC.

Summary

• On December 31, 2024, Alan R. Stewart, a director of Calidi Biotherapeutics, engaged in transactions involving the company's common stock.
• Stewart acquired 12,771 shares of common stock through a grant of restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan.
• These RSUs fully vested on the grant date and represent a right to receive one share of common stock upon vesting.
• The price per share for the RSU grant was $1.15, based on the closing price of Calidi Biotherapeutics' stock on December 31, 2024.
• Concurrently, Stewart disposed of 28,976 shares.
• Following these transactions, Stewart's beneficial ownership of common stock is 28,976 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock transactions by a company director. The acquisition of RSUs is generally positive, but the disposal of shares tempers the sentiment.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.
• The RSUs fully vested on the grant date.

Negatives

• The director disposed of 28,976 shares of common stock on the same day as acquiring RSUs.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence in the company.

Key Dates